Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
1.
J Am Soc Nephrol ; 33(2): 326-341, 2022 02.
Article in English | MEDLINE | ID: mdl-34799437

ABSTRACT

BACKGROUND: Hereditary renal hypouricemia type 1 (RHUC1) is caused by URAT1/SLC22A12 dysfunction, resulting in urolithiasis and exercise-induced AKI (EIAKI). However, because there is no useful experimental RHUC1 animal model, the precise pathophysiologic mechanisms underlying EIAKI have yet to be elucidated. We established a high HPRT activity Urat1-Uox double knockout (DKO) mouse as a novel RHUC1 animal model for investigating the cause of EIAKI and the potential therapeutic effect of xanthine oxidoreductase inhibitors (XOIs). METHODS: The novel Urat1-Uox DKO mice were used in a forced swimming test as loading exercise to explore the onset mechanism of EIAKI and evaluate related purine metabolism and renal injury parameters. RESULTS: Urat1-Uox DKO mice had uricosuric effects and elevated levels of plasma creatinine and BUN as renal injury markers, and decreased creatinine clearance observed in a forced swimming test. In addition, Urat1-Uox DKO mice had increased NLRP3 inflammasome activity and downregulated levels of Na+-K+-ATPase protein in the kidney, as Western blot analysis showed. Finally, we demonstrated that topiroxostat and allopurinol, XOIs, improved renal injury and functional parameters of EIAKI. CONCLUSIONS: Urat1-Uox DKO mice are a useful experimental animal model for human RHUC1. The pathogenic mechanism of EIAKI was found to be due to increased levels of IL-1ß via NLRP3 inflammasome signaling and Na+-K+-ATPase dysfunction associated with excessive urinary urate excretion. In addition, XOIs appear to be a promising therapeutic agent for the treatment of EIAKI.


Subject(s)
Acute Kidney Injury/drug therapy , Hypoxanthine Phosphoribosyltransferase/metabolism , Organic Anion Transporters/deficiency , Urate Oxidase/deficiency , Xanthine Dehydrogenase/antagonists & inhibitors , Acute Kidney Injury/etiology , Acute Kidney Injury/metabolism , Allopurinol/pharmacology , Animals , Disease Models, Animal , Enzyme Inhibitors/pharmacology , Hypoxanthine Phosphoribosyltransferase/genetics , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Nitriles/pharmacology , Organic Anion Transporters/genetics , Physical Exertion , Pyridines/pharmacology , Renal Tubular Transport, Inborn Errors/drug therapy , Renal Tubular Transport, Inborn Errors/etiology , Renal Tubular Transport, Inborn Errors/metabolism , Sodium-Potassium-Exchanging ATPase/metabolism , Urate Oxidase/genetics , Urinary Calculi/drug therapy , Urinary Calculi/etiology , Urinary Calculi/metabolism
3.
Anticancer Res ; 40(12): 7135-7140, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33288613

ABSTRACT

AIM: To clarify the differences in overall survival (OS) depending on the presence or absence of hypomagnesemia and the type of epidermal growth factor receptor antibody as first-line therapy for metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: We retrospectively compared the OS in 68 patients who received cetuximab or panitumumab for mCRC at Ogaki Municipal Hospital (Ogaki, Japan) between January 2010 and December 2019. RESULTS: The complete and partial response rates in the cetuximab and panitumumab groups were 60.0% and 72.0%, respectively (p=0.470). The OS was significantly longer in the panitumumab group (median=1,007 days, range=208-1,433 days) than in the cetuximab group (median=735 days, range=181-2,391 days; p=0.047). Hypomagnesemia did not contribute to differences in OS in the two groups. CONCLUSION: Panitumumab may lead to a longer OS than cetuximab as first-line treatment of mCRC. The presence or absence of hypomagnesemia in cetuximab- or panitumumab-treated patients did not affect OS.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Colorectal Neoplasms/drug therapy , ErbB Receptors/therapeutic use , Hypercalciuria/drug therapy , Nephrocalcinosis/drug therapy , Renal Tubular Transport, Inborn Errors/drug therapy , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/pharmacology , Colorectal Neoplasms/mortality , ErbB Receptors/pharmacology , Female , Humans , Hypercalciuria/etiology , Male , Middle Aged , Nephrocalcinosis/etiology , Renal Tubular Transport, Inborn Errors/etiology , Retrospective Studies , Survival Analysis
4.
Clin Rheumatol ; 39(1): 135-147, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31650389

ABSTRACT

We presented an update in the field of hypouricemia, which is defined as a serum urate concentration of < 2 mg/dL (119 µmol/L), for the practicing rheumatologist, who usually is the consulting physician in cases of disorders of urate metabolism. We performed a narrative review through a literature search for original and review articles in the field of human hypouricemia published between January 1950 and July 2018. We divided the etiology of hypouricemia into two main categories: those associated with a decrease in urate production and those promoting the elimination of urate via the kidneys. The most common conditions associated with these categories are discussed. Furthermore, the etiology of hypouricemia may be associated with certain medications prescribed by the practicing rheumatologists, such as the following: urate-lowering drugs (allopurinol and febuxostat); recombinant uricase (pegloticase); uricosuric agents (probenecid, benzbromarone); urate transporter URAT1 inhibitor (lesinurad); angiotensin II receptor blocker (losartan); fenofibrate; high-dose trimethoprim-sulfamethoxazole; some NSAID; and high-dose salicylate therapy. The rheumatologist is considered an expert in the metabolism of urate and its associated pathological conditions. Therefore, specialists must recognize hypouricemia as a biomarker of various pathological and potentially harmful conditions, highlighting the importance of conducting a deeper clinical investigation to reach a more accurate diagnosis and treatment.


Subject(s)
Renal Tubular Transport, Inborn Errors/diagnosis , Renal Tubular Transport, Inborn Errors/drug therapy , Uricosuric Agents/therapeutic use , Urinary Calculi/diagnosis , Urinary Calculi/drug therapy , Biomarkers , Humans , Rheumatologists
6.
Semin Dial ; 31(1): 11-14, 2018 01.
Article in English | MEDLINE | ID: mdl-29063671

ABSTRACT

Even though disorders of magnesium (Mg) balance are common in dialyzed patients, this cation is often neglected. Many factors interfere with serum magnesium including diet, medications (eg, antacids or phosphate binders), and the dialysis prescription. Mg supplementation may help reduce serum phosphate concentration, PTH, and interfere with vascular calcification and bone mineralization. It could also decrease the all-cause and cardiovascular mortalities, although the results of current studies are conflicting. As with many other variables that influence hard endpoints in nephrology, additional research directly targeting the role of Mg supplementation in dialyzed patients are required. Nevertheless, a current risk/benefit assessment suggests that supplementation of Mg targeting high normal serum levels may represent a plausible option to improve the outcome of dialysis patients.


Subject(s)
Dietary Supplements , Kidney Failure, Chronic/therapy , Magnesium/administration & dosage , Renal Dialysis/adverse effects , Renal Tubular Transport, Inborn Errors/drug therapy , Renal Tubular Transport, Inborn Errors/etiology , Female , Humans , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/mortality , Magnesium/blood , Male , Prognosis , Renal Dialysis/methods , Renal Tubular Transport, Inborn Errors/physiopathology , Risk Assessment , Survival Analysis , Treatment Outcome
7.
Nutrition ; 38: 54-60, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28526383

ABSTRACT

OBJECTIVES: Recent studies have demonstrated that minerals play a role in glucose metabolism disorders in humans. Magnesium, in particular, is an extensively studied mineral that has been shown to function in the management of hyperglycemia, hyperinsulinemia, and insulin resistance (IR) action. The aim of this study was to investigate the effect of magnesium supplementation on IR in humans via systematic review of the available clinical trials. METHODS: This review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. A survey was conducted to select clinical trials related to the effects of this mineral in insulin sensitivity using the following databases: PubMed, SciVerse Scopus, ScienceDirect, and SciVerse Cochrane. RESULTS: After the selection process, 12 articles were identified as eligible, representing different clinical conditions and being free of restriction with regard to sex, age, ethnicity, and differential dosing/shape of magnesium. The results of eight clinical trials showed that supplementation with magnesium influences serum fasting glucose concentrations, and five trials determined an effect on fasting insulin levels. The results of seven studies demonstrated that mineral supplementation reduced homeostasis model assessment for IR values. CONCLUSIONS: The data of this systematic review provide evidence as to the benefits of magnesium supplementation in reducing IR in patients with hypomagnesemia presenting IR. However, new intervention studies are needed to elucidate the role of the nutrient in protection against this metabolic disorder, as well as the standardization of the type, dose, and time of magnesium supplementation.


Subject(s)
Blood Glucose/drug effects , Dietary Supplements , Hypercalciuria/drug therapy , Insulin Resistance , Magnesium/therapeutic use , Nephrocalcinosis/drug therapy , Renal Tubular Transport, Inborn Errors/drug therapy , Humans
8.
Pediatr Nephrol ; 32(7): 1123-1135, 2017 Jul.
Article in English | MEDLINE | ID: mdl-27234911

ABSTRACT

Magnesium is essential to the proper functioning of numerous cellular processes. Magnesium ion (Mg2+) deficits, as reflected in hypomagnesemia, can cause neuromuscular irritability, seizures and cardiac arrhythmias. With normal Mg2+ intake, homeostasis is maintained primarily through the regulated reabsorption of Mg2+ by the thick ascending limb of Henle's loop and distal convoluted tubule of the kidney. Inadequate reabsorption results in renal Mg2+ wasting, as evidenced by an inappropriately high fractional Mg2+ excretion. Familial renal Mg2+ wasting is suggestive of a genetic cause, and subsequent studies in these hypomagnesemic families have revealed over a dozen genes directly or indirectly involved in Mg2+ transport. Those can be classified into four groups: hypercalciuric hypomagnesemias (encompassing mutations in CLDN16, CLDN19, CASR, CLCNKB), Gitelman-like hypomagnesemias (CLCNKB, SLC12A3, BSND, KCNJ10, FYXD2, HNF1B, PCBD1), mitochondrial hypomagnesemias (SARS2, MT-TI, Kearns-Sayre syndrome) and other hypomagnesemias (TRPM6, CNMM2, EGF, EGFR, KCNA1, FAM111A). Although identification of these genes has not yet changed treatment, which remains Mg2+ supplementation, it has contributed enormously to our understanding of Mg2+ transport and renal function. In this review, we discuss general mechanisms and symptoms of genetic causes of hypomagnesemia as well as the specific molecular mechanisms and clinical phenotypes associated with each syndrome.


Subject(s)
Arrhythmias, Cardiac/blood , Hypercalciuria/genetics , Magnesium Deficiency/genetics , Magnesium/blood , Nephrocalcinosis/genetics , Renal Elimination/genetics , Renal Reabsorption/genetics , Renal Tubular Transport, Inborn Errors/genetics , Seizures/blood , Arrhythmias, Cardiac/etiology , Child , Epithelial Sodium Channel Blockers/therapeutic use , Homeostasis/genetics , Humans , Hypercalciuria/blood , Hypercalciuria/complications , Hypercalciuria/drug therapy , Hypokalemia/blood , Hypokalemia/drug therapy , Hypokalemia/etiology , Hypokalemia/genetics , Kidney Tubules, Distal/physiology , Loop of Henle/physiology , Magnesium/physiology , Magnesium/therapeutic use , Magnesium Deficiency/complications , Magnesium Deficiency/drug therapy , Membrane Proteins/genetics , Membrane Proteins/metabolism , Mineralocorticoid Receptor Antagonists/therapeutic use , Mitochondria/metabolism , Mutation , Nephrocalcinosis/blood , Nephrocalcinosis/complications , Nephrocalcinosis/drug therapy , Phenotype , Recommended Dietary Allowances , Renal Reabsorption/drug effects , Renal Tubular Transport, Inborn Errors/blood , Renal Tubular Transport, Inborn Errors/complications , Renal Tubular Transport, Inborn Errors/drug therapy , Seizures/etiology
9.
Nucleosides Nucleotides Nucleic Acids ; 35(10-12): 543-549, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27906636

ABSTRACT

Renal hypouricemia (RHUC) is a hereditary disease characterized by a low level of plasma urate but with normal urinary urate excretion. RHUC type 1 is caused by mutations of the urate transporter URAT1 gene (SLC22A12). However, the plasma urate levels of URAT1 knockout mice are no different from those of wild-type mice. In the present study, a double knockout mouse, in which the URAT1 and uricase (Uox) genes were deleted (Urat1-Uox-DKO), were used as an experimental animal model of RHUC type 1 to investigate RHUC and excise-induced acute kidney injury (EIAKI). Mice were given a variable content of allopurinol for one week followed by HPLC measurement of urate and creatinine concentrations in spot urine and blood from the tail. The urinary excretion of urate in Urat1-Uox-DKO mice was approximately 25 times higher than those of humans. With allopurinol, the plasma urate levels of Urat1-Uox-DKO mice were lower than those of Uox-KO mice. There were no differences in the urinary urate excretions between Urat1-Uox-DKO and Uox-KO mice administered with 9 mg allopurinol /100 g feed. In the absence of allopurinol, plasma creatinine levels of some Urat1-Uox-DKO mice were higher than those of Uox-KO mice. Consequently, hypouricemia and normouricosuria may indicate that the Urat1-Uox-DKO mouse administered with allopurinol may represent a suitable animal model of RHUC type 1. Urat1-Uox-DKO mice without allopurinol exhibited acute kidney injury, thus providing additional benefit as a potential animal model for EIAKI. Finally, our data indicate that allopurinol appears to provide prophylactic effects for EIAKI.


Subject(s)
Acute Kidney Injury/genetics , Organic Anion Transporters/genetics , Renal Tubular Transport, Inborn Errors/genetics , Urate Oxidase/genetics , Urinary Calculi/genetics , Acute Kidney Injury/drug therapy , Acute Kidney Injury/metabolism , Allopurinol/pharmacology , Allopurinol/therapeutic use , Animals , Creatinine/blood , Disease Models, Animal , Gout Suppressants/pharmacology , Gout Suppressants/therapeutic use , Male , Mice, Knockout , Organic Anion Transporters/metabolism , Physical Conditioning, Animal , Renal Tubular Transport, Inborn Errors/drug therapy , Renal Tubular Transport, Inborn Errors/metabolism , Urate Oxidase/metabolism , Uric Acid/urine , Urinary Calculi/drug therapy , Urinary Calculi/metabolism
10.
Pediatr Nephrol ; 31(3): 407-18, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26178649

ABSTRACT

At least three renal tubular segments are involved in the pathophysiology of salt-losing tubulopathies (SLTs). Whether the pathogenesis starts either in the thick ascending limb of the loop of Henle (TAL) or in the distal convoluted tubule (DCT), it is the function of the downstream-localized aldosterone sensitive distal tubule (ASDT) to contribute to the adaptation process. In isolated TAL defects (loop disorders) ASDT adaptation is supported by upregulation of DCT, whereas in DCT disorders the ASDT is complemented by upregulation of TAL function. This upregulation has a major impact on the clinical presentation of SLT patients. Taking into account both the symptoms and signs of primary tubular defect and of the secondary reactions of adaptation, a clinical diagnosis can be made that eventually leads to an appropriate therapy. In addition to salt wasting, as occurs in all SLTs, characteristic features of loop disorders are hypo- or isosthenuric polyuria and hypercalciuria, whereas characteristics of DCT disorders are hypokalemia and (symptomatic) hypomagnesemia. In both SLT categories, replacement of urinary losses is the primary goal of treatment. In loop disorders COX inhibitors are also recommended to mitigate polyuria, and in DCT disorders magnesium supplementation is essential for effective treatment. Of note, the combination of a salt- and potassium-rich diet together with an adequate fluid intake is always the basis of long-term treatment in all SLTs.


Subject(s)
Kidney Tubules, Distal/physiopathology , Renal Tubular Transport, Inborn Errors/physiopathology , Water-Electrolyte Balance , Adaptation, Physiological , Animals , Calcium/metabolism , Humans , Hyperaldosteronism/etiology , Hyperaldosteronism/physiopathology , Kidney Tubules, Distal/drug effects , Kidney Tubules, Distal/metabolism , Magnesium/metabolism , Renal Agents/therapeutic use , Renal Reabsorption , Renal Tubular Transport, Inborn Errors/complications , Renal Tubular Transport, Inborn Errors/drug therapy , Renal Tubular Transport, Inborn Errors/metabolism , Sodium Chloride/metabolism , Water/metabolism , Water-Electrolyte Balance/drug effects
11.
Transplant Rev (Orlando) ; 29(3): 154-60, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26001746

ABSTRACT

In the era of calcineurin inhibitors, hypomagnesaemia is a very common finding in kidney transplant recipients. Especially the first weeks after transplantation it is the rule rather than the exception. Hypomagnesaemia or low magnesium intake have been associated with a higher mortality or more cardiovascular events in the general population, but this association has never been explored in kidney transplant recipients, despite their increased cardiovascular risk. Kidney transplant recipients with pre- or post-transplant hypomagnesaemia seem to have an aberrant glucose metabolism and develop diabetes mellitus more frequently. Moreover, observations from alternate study populations, animal experiments or in vitro studies suggest a possible role of magnesium deficiency in graft dysfunction, bone metabolism and transplant immunology. Future observational and especially interventional studies should further define whether and to what extent we should make effort to correct this electrolyte disturbance in transplant recipients. Considering the mechanism of renal magnesium wasting, normalizing the serum magnesium concentration by oral supplementation alone might turn out to be cumbersome in kidney transplant recipients.


Subject(s)
Calcineurin Inhibitors/adverse effects , Kidney Transplantation/adverse effects , Magnesium/blood , Renal Tubular Transport, Inborn Errors/etiology , Calcineurin Inhibitors/therapeutic use , Female , Follow-Up Studies , Graft Rejection , Graft Survival , Humans , Kidney Transplantation/methods , Magnesium/metabolism , Magnesium Deficiency/etiology , Magnesium Deficiency/physiopathology , Male , Postoperative Complications/epidemiology , Postoperative Complications/physiopathology , Renal Tubular Transport, Inborn Errors/drug therapy , Renal Tubular Transport, Inborn Errors/physiopathology , Risk Assessment
12.
Anticancer Res ; 35(4): 2199-204, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25862878

ABSTRACT

AIM: The present study aimed to assess the efficacy of 15 mEq magnesium supplied as part of a prehydration regimen in preventing cisplatin-induced nephrotoxicity in patients undergoing therapy with cisplatin-alone (40 mg/m(2)/week) for cervical cancer. PATIENTS AND METHODS: We studied 28 patients with cervical cancer. This prospective cohort study compared nephrotoxicity in patients who received hydration with and without magnesium sulfate (Mg-hydration group, n=14; non-Mg-hydration group, n=14). RESULTS: Baseline characteristics, stage of cervical cancer, cisplatin dose and renal function did not differ significantly between the two groups. The serum creatinine level significantly increased from 0.58 to 0.75 mg/dl, and the estimated glomerular filtration rate significantly decreased from 85.1 to 66.5 ml/min by chemotherapy in the non-Mg-hydration group. In contrast, these levels did not change significantly in the Mg-hydration group. CONCLUSION: A magnesium dose of 15 mEq was found to provide nephroprotective effects among patients with cervical cancer undergoing chemotherapy with cisplatin alone.


Subject(s)
Cisplatin/administration & dosage , Magnesium/administration & dosage , Renal Insufficiency/drug therapy , Uterine Cervical Neoplasms/drug therapy , Adult , Aged , Cisplatin/adverse effects , Disease-Free Survival , Female , Humans , Hypercalciuria/chemically induced , Hypercalciuria/drug therapy , Hypercalciuria/pathology , Hypodermoclysis , Kidney/drug effects , Male , Middle Aged , Neoplasm Staging , Nephrocalcinosis/chemically induced , Nephrocalcinosis/drug therapy , Nephrocalcinosis/pathology , Renal Insufficiency/chemically induced , Renal Tubular Transport, Inborn Errors/chemically induced , Renal Tubular Transport, Inborn Errors/drug therapy , Renal Tubular Transport, Inborn Errors/pathology , Uterine Cervical Neoplasms/pathology
13.
Brain Dev ; 37(3): 292-8, 2015 Mar.
Article in English | MEDLINE | ID: mdl-24985022

ABSTRACT

BACKGROUND: TRPM6 gene mutation has been reported to cause hypomagnesemia with secondary hypocalcemia (HSH). However, the genotype-phenotype correlation for TRPM6 gene mutations has not been clarified. OBJECTIVE: To elucidate the factors underlying the severe neurological complications in HSH and evaluate the potential association between the location of TRPM6 gene mutations and clinical data of HSH. METHODS: A Japanese patient diagnosed with HSH at 10 weeks of age exhibited neurological damage and failed to thrive. Magnesium supplements were therefore started at 12 weeks of age. Mutational analysis of the TRPM6 gene was performed using a direct sequencing method to determine the position and type of mutation. Using the data of 29 HSH patients reported in the literature, linear regression analysis was also performed to examine the association between TRPM6 gene mutation location and HSH onset age, initial serum magnesium and calcium concentrations, and dose of oral magnesium. RESULTS: A novel stop-codon homozygous mutation [c.4190 G>A] W1397X was identified in exon 26 of the patient's TRPM6 gene. No statistical correlation was found between the location of mutations in the TRPM6 gene and the clinical data for 4 clinical indicators of HSH. CONCLUSIONS: We identified the first Japanese HSH patient with a novel nonsense mutation in the TRPM6 gene. Regression analysis of mutation locations in the protein-coding region of TRPM6 and the reported clinical data for 4 clinical indicators of HSH in 30 HSH patients did not detect a genotype-phenotype correlation.


Subject(s)
Hypocalcemia/genetics , Renal Tubular Transport, Inborn Errors/genetics , TRPM Cation Channels/genetics , Codon, Nonsense , Female , Humans , Hypocalcemia/drug therapy , Infant , Japan , Magnesium Deficiency/congenital , Renal Tubular Transport, Inborn Errors/drug therapy
14.
Arch Med Res ; 45(4): 325-30, 2014 May.
Article in English | MEDLINE | ID: mdl-24814039

ABSTRACT

BACKGROUND AND AIMS: It has been suggested that magnesium deficiency is associated with the triggering of acute phase response, which may contribute to type 2 diabetes and cardiovascular disease risk. We undertook this study to determine whether oral magnesium supplementation modifies serum levels of high-sensitivity C-reactive protein (hsCRP) in apparently healthy subjects with prediabetes and hypomagnesemia. METHODS: A total of 62 men and non-pregnant women aged 18-65 year, with new diagnosis of prediabetes (glucose 5.6 <7.0 mmol/L and/or post-load glucose ≥7.7 <11.1 mmol/L) and hypomagnesemia (serum magnesium levels <0.74 mmol/L) were enrolled in a clinical double-blind placebo-controlled trial and randomly allocated to receive either magnesium chloride (30 mL of MgCl2 5% solution) or NaHCO3 0.1% solution, once daily for 3 months. RESULTS: At basal conditions, anthropometric and biochemical variables were similarly distributed in both groups. At the end of follow-up, participants who received magnesium chloride showed higher serum magnesium levels (0.86 ± 0.08 vs. 0.69 ± 0.16 mmol/L, p = 0.002) and lower hsCRP levels (4.8 ± 15.2 vs. 17.1 ± 21.0 nmol/L, p = 0.01) compared with participants in the control group. CONCLUSIONS: Oral magnesium supplementation decreases hsCRP levels in apparently healthy subjects with prediabetes and hypomagnesemia.


Subject(s)
C-Reactive Protein/metabolism , Diabetes Mellitus, Type 2/drug therapy , Hypercalciuria/drug therapy , Magnesium Chloride/administration & dosage , Nephrocalcinosis/drug therapy , Prediabetic State/drug therapy , Renal Tubular Transport, Inborn Errors/drug therapy , Administration, Oral , Adolescent , Adult , Aged , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/metabolism , Dietary Supplements , Double-Blind Method , Female , Humans , Hypercalciuria/complications , Hypercalciuria/metabolism , Magnesium Chloride/blood , Male , Middle Aged , Nephrocalcinosis/complications , Nephrocalcinosis/metabolism , Prediabetic State/complications , Prediabetic State/metabolism , Renal Tubular Transport, Inborn Errors/complications , Renal Tubular Transport, Inborn Errors/metabolism , Young Adult
16.
J Pediatr Hematol Oncol ; 36(4): 305-7, 2014 May.
Article in English | MEDLINE | ID: mdl-23426003

ABSTRACT

Cetuximab, a monoclonal antibody specific for epidermal growth factor receptor, is increasingly used off-label and in early-phase trials for pediatric malignancies. Here, we report a patient with metastatic medulloblastoma receiving therapy with cyclophosphamide, vinblastine, and cetuximab. During evaluation for possible seizures, he was noted to be severely hypocalcemic, hypokalemic, and hypomagnesemic, a consequence of the blockade of renal epidermal growth factor receptor expression. His symptoms rapidly abated with intravenous electrolyte repletion. This case highlights the clinical heterogeneity of tetany and the importance of careful laboratory screening for known adverse effects of chemotherapy, particularly when newer biological agents are used off-study in combination chemotherapeutic regimens.


Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Agents/adverse effects , Cerebellar Neoplasms/drug therapy , Electrolytes/administration & dosage , Hypercalciuria , Medulloblastoma/drug therapy , Nephrocalcinosis , Renal Tubular Transport, Inborn Errors , Tetany/drug therapy , Antibodies, Monoclonal, Humanized/administration & dosage , Antineoplastic Agents/administration & dosage , Cerebellar Neoplasms/pathology , Cetuximab , Child, Preschool , Humans , Hypercalciuria/chemically induced , Hypercalciuria/drug therapy , Male , Medulloblastoma/pathology , Neoplasm Metastasis , Nephrocalcinosis/chemically induced , Nephrocalcinosis/drug therapy , Renal Tubular Transport, Inborn Errors/chemically induced , Renal Tubular Transport, Inborn Errors/drug therapy , Seizures/chemically induced , Seizures/drug therapy , Tetany/chemically induced
17.
BMC Res Notes ; 6: 527, 2013 Dec 10.
Article in English | MEDLINE | ID: mdl-24321194

ABSTRACT

BACKGROUND: Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis is a rare tubulopathy leading to renal calcification and progressive renal failure. CASE PRESENTATION: We report a consanguineous Arab family (of Qatari origin) with 7 affected siblings with variable phenotypes including hypomagnesaemia, hypercalciuria, nephrocalcinosis and renal stones. Presenting features included haematuria and recurrent urinary tract infections. As the biochemical and clinical phenotypes of this family resembled familial hypomagnesaemia with hypercalciuria and nephrocalcinosis, we performed genetic investigation in order to provide a precise molecular diagnosis. We screened all coding regions of the CLDN16 gene and identified a novel mutation (c.G647A, p.R216H) which was found homozygously in the six severely affected cases, who manifested significant nephrocalcinosis, often nephrolithiasis and sometimes reduced GFR. Parents were both heterozygous for the mutation and, together with children carrying the mutation in its heterozygous state, exhibited mild or no biochemical phenotypes. CONCLUSION: Mutations in CLDN16 underlie familial hypomagnesaemia with hypercalciuria and nephrocalcinosis but remain a rare cause of nephrocalcinosis and nephrolithiasis. Management includes reduction of hypercalciuria with thiazide diuretics, correction of serum magnesium and close monitoring of renal function given the significant risk of end stage renal failure with this inherited form of nephrocalcinosis.


Subject(s)
Claudins/genetics , Hypercalciuria/genetics , Mutation , Nephrocalcinosis/genetics , Renal Tubular Transport, Inborn Errors/genetics , Adult , Child , Child, Preschool , Consanguinity , Female , Heterozygote , Homozygote , Humans , Hypercalciuria/drug therapy , Hypercalciuria/metabolism , Hypercalciuria/pathology , Infant , Kidney/metabolism , Kidney/pathology , Magnesium/administration & dosage , Male , Nephrocalcinosis/drug therapy , Nephrocalcinosis/metabolism , Nephrocalcinosis/pathology , Pedigree , Phenotype , Renal Tubular Transport, Inborn Errors/drug therapy , Renal Tubular Transport, Inborn Errors/metabolism , Renal Tubular Transport, Inborn Errors/pathology , Sodium Chloride Symporter Inhibitors/therapeutic use
18.
Diabetes Metab Syndr ; 7(1): 35-7, 2013.
Article in English | MEDLINE | ID: mdl-23517794

ABSTRACT

BACKGROUND: Higher levels of lipid peroxidation and hypomagnesaemia are frequently associated with Type 2 Diabetes mellitus (T2DM). Addressing these issues would definitely help us in preventing or prolonging the onset of pathogenesis of micro and macrovascular complications. Pioglitazone is used as a trusted insulin sensitizer and an adjuvant to the conventional oral hypoglycemic agents. This study was planned to explore the effects of pioglitazone on oxidative stress, serum magnesium, blood pressure, hepato-biliary and renal systems in addition to its effects on glycemic control. METHODS: Sixty-three T2DM cases, who were started on pioglitazone were included in this study. All the physiological and biochemical parameters were estimated prior to and following three months of therapy with pioglitazone. RESULTS: There was significant improvement in the glycemic control, serum magnesium and MDA levels with p values of 0.000, 0.023 and 0.000 respectively. Pioglitazone did not have any significant effects on the serum lipids and blood pressure in T2DM cases following three months of treatment. We did not observe any pronounced changes in hepato-biliary enzymes, serum urea and creatinine levels reaffirming safety of pioglitazone in T2DM. CONCLUSION: Three-month duration of treatment with Pioglitazone in T2DM cases helps in alleviating the levels of lipid peroxides, besides being associated with improved serum magnesium status and glycemic control.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Diabetic Nephropathies/drug therapy , Hypoglycemic Agents/therapeutic use , Lipid Peroxides/blood , Magnesium/metabolism , Renal Tubular Transport, Inborn Errors/drug therapy , Thiazolidinediones/therapeutic use , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/metabolism , Diabetic Nephropathies/epidemiology , Diabetic Nephropathies/metabolism , Female , Glycated Hemoglobin/metabolism , Humans , India/epidemiology , Kidney/drug effects , Kidney/metabolism , Lipid Peroxidation/drug effects , Lipid Peroxides/metabolism , Male , Middle Aged , Oxidative Stress/drug effects , Pioglitazone , Renal Tubular Transport, Inborn Errors/epidemiology , Renal Tubular Transport, Inborn Errors/metabolism
19.
Magnes Res ; 25(4): 159-67, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23262475

ABSTRACT

Hypomagnesemia has been linked with increased morbidity and mortality in critically ill patients. Since the condition is common after cardiopulmonary bypass surgery, the objective of this study was to determine whether magnesium supplementation in the immediate postoperative period may improve outcomes of patients undergoing cardiac surgery with cardiopulmonary bypass. This prospective, randomized, double-blind, placebo-controlled study was conducted in a third-level, cardiac surgery intensive care unit (ICU) at a university hospital. Two hundred and sixteen patients undergoing elective cardiac surgery with cardiopulmonary bypass were randomized to receive either an intravenous bolus of 1.5 g of magnesium sulphate followed by an infusion of 12 g of the same salt in 24 h (105 patients), or placebo (111 patients) administered according to the same schedule as the treatment group. No significant differences were found either in the primary end point (hours of intubation) or in the secondary end points (length of inotropic support, new atrial fibrillation, ventricular tachycardia or ventricular fibrillation, length of intensive care unit stay, or ICU or hospital mortality). Hypomagnesemia was present in 12% of patients on admission to the intensive care unit. The magnesium group had a greater need for pacemaker stimulation. In conclusion, under the conditions of the present study, magnesium supplementation after cardiac surgery with cardiopulmonary bypass does not favourably affect clinical outcomes.


Subject(s)
Cardiac Surgical Procedures/adverse effects , Dietary Supplements , Magnesium Sulfate/administration & dosage , Postoperative Complications/drug therapy , Aged , Double-Blind Method , Female , Humans , Hypercalciuria/blood , Hypercalciuria/diagnosis , Hypercalciuria/drug therapy , Magnesium Sulfate/blood , Male , Middle Aged , Nephrocalcinosis/blood , Nephrocalcinosis/diagnosis , Nephrocalcinosis/drug therapy , Postoperative Complications/blood , Postoperative Complications/diagnosis , Prospective Studies , Renal Tubular Transport, Inborn Errors/blood , Renal Tubular Transport, Inborn Errors/diagnosis , Renal Tubular Transport, Inborn Errors/drug therapy , Treatment Outcome
20.
Magnes Res ; 25(3): 140-6, 2012.
Article in English | MEDLINE | ID: mdl-23073360

ABSTRACT

To determine whether oral magnesium supplementation modifies serum levels of high-sensitivity C-reactive protein (hsCRP), TNF-alpha, IL-6, and IL-10 in subjects with prediabetes, inflammation, and hypomagnesemia, a total of 26 subjects men and non-pregnant women were included and randomly allocated to receive 30 ml of MgCl(2) 5% solution (equivalent to 382 mg of magnesium) or placebo, daily during three months. At baseline conditions, there were not significant statistical differences between the groups. At end of the study, hsCRP levels were significantly lower in the intervention group (3.3 ± 2.5 vs 8.0 ± 5.9 mg/L, p = 0.03), as compared with the control group. However, the intra-group analysis of the individuals who received magnesium, did not shows significant statistical differences between baseline and final conditions (4.1 ± 3.0 and 3.3 ± 2.5, p = 0.45). In addition, TNF-alpha (1.2 ± 0.3 vs 1.1 ± 0.3 pg/mL, p = 0.69), IL-6 (0.3 ± 0.3 vs 5.0 ± 7.7 pg/mL, p = 0.08), and IL-10 (1.8 ± 0.4 vs 1.8 ± 0.5 pg/mL, p = 0.89) serum levels were not significantly different between the groups. Our results do not show a beneficial effect of oral magnesium supplementation on hsCRP, IL-6, TNF-alpha, and IL-10 levels in prediabetic subjects with hypomagnesemia and inflammation. Further studies with large sample sizes and longer time of follow-up are necessaries to verify the results of our pilot study.


Subject(s)
Dietary Supplements , Inflammation/complications , Magnesium/administration & dosage , Magnesium/pharmacology , Prediabetic State/complications , Administration, Oral , Adult , Aged , C-Reactive Protein/analysis , Female , Humans , Hypercalciuria/drug therapy , Inflammation/drug therapy , Inflammation/prevention & control , Interleukin-10/blood , Interleukin-6/blood , Male , Middle Aged , Nephrocalcinosis/drug therapy , Pilot Projects , Prediabetic State/drug therapy , Renal Tubular Transport, Inborn Errors/drug therapy , Tumor Necrosis Factor-alpha/blood , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...